Skip to search formSkip to main contentSkip to account menu

PM02734

Known as: Depsipeptide PM02734 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Irvalecelisidepsin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors
This first-in-human, phase I clinical trial was designed to determine the dose-limiting toxicities (DLTs) and the dose for phase… 
2013
2013
Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound
Elisidepsin (PM02734, Irvalec®) is a synthetic marine-derived cyclic peptide of the Kahalalide F family currently in phase II… 
2012
2012
A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors
PurposeTo determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and recommended phase II dose (RD) of… 
Highly Cited
2011
Highly Cited
2011
PM02734 (Elisidepsin) Induces Caspase-Independent Cell Death Associated with Features of Autophagy, Inhibition of the Akt/mTOR Signaling Pathway, and Activation of Death-Associated Protein Kinase
Purpose: PM02734 (elisidepsin) is a synthetic marine-derived cyclic peptide of the kahalalide family currently in phase II… 
2009
2009
Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
Review
2009
Review
2009
Cancer treatments: can we find treasures at the bottom of the sea?
Because of the poor results observed after platinum-based first-line chemotherapy, research on new strategies for second-line… 
2008
2008
Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734.
PM02734 is a novel synthetic antitumor drug that is currently in phase I clinical trials. To gain some insight into its mode of… 
2008
2008
Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations
2513 Background: PM02734 is a chemically synthesized depsipeptide with a broad spectrum of activity against solid tumors in vitro… 
2006
2006
Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma.
A rapid and sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) assay was developed and validated to quantify a… 
2006
2006
Activity of pm02734 against human breast and prostate tumors
4712 The novel investigational agent PM02734 is a member of the Kahalalide F family of compounds that display marked anttumor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)